Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Clinical Question·Updated Jul 2, 2026·v1

Role of SBRT in Oligometastatic NSCLC [DeepSeek Max]

Evidence-based overview of Role of SBRT in metastatic lung cancer.

Moderate Evidence23 references·1,657 words·7 min read·v1
Radiation Oncologyrole of sbrt in metastatic lung cancer
This page covers Role of SBRT in metastatic lung cancer, a topic in Radiation Oncology.

Deep Dive — Evidence Details

References

  1. [1]

    Cho BC, Lim SM, Lee SH et al.. “MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42103553 ↗

    L2RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  2. [2]

    Ghiringhelli F, Lawrence YR, Felip E et al.. “Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.” Journal for immunotherapy of cancer (2025). PMID: 40759444 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  3. [3]

    Zhang R, Chen M, Yin N et al.. “Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).” BMJ open (2025). PMID: 40887121 ↗

    L5TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  4. [4]

    Filippi AR, Rulli E, Signorelli D et al.. “Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.” Clinical lung cancer (2025). PMID: 40781023 ↗

    L5TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  5. [5]

    Huang J, Theelen WSME, Belcaid Z et al.. “Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.” Nature cancer (2025). PMID: 40696153 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  6. [6]

    Chuong MD, Mittauer KE, Bassetti MF et al.. “Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40158734 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  7. [7]

    Keane FK, Yeap BY, Khandekar MJ et al.. “Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.” International journal of radiation oncology, biology, physics (2024). PMID: 39577475 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  8. [8]

    Levy A, Adebahr S, Hurkmans C et al.. “Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024). PMID: 38788924 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  9. [9]

    Franceschini D, Franzese C, Comito T et al.. “Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024). PMID: 38522597 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Levy A, Morel D, Texier M et al.. “An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.” Molecular cancer (2024). PMID: 38519913 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
  11. [11]

    Zeng H, Wang X, Bai H et al.. “Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis.” Radiation oncology (London, England) (2026). PMID: 42116164 ↗

    L2SR_OBSCited in: Current Evidence and Standard
  12. [12]

    Gooijer SA, Gazendam ASM, Torensma B et al.. “Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 40300380 ↗

    L2SR_OBSCited in: Current Evidence and Standard
  13. [13]

    Mayinger M, Kotecha R, Sahgal A et al.. “Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.” Lung cancer (Amsterdam, Netherlands) (2023). PMID: 37390723 ↗

    L1GUIDELINECited in: Applicability and Caveats
  14. [14]

    Iyengar P, All S, Berry MF et al.. “Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.” Practical radiation oncology (2023). PMID: 37294262 ↗

    L1GUIDELINECited in: Applicability and Caveats
  15. [15]

    Simone CB, Bogart JA, Cabrera AR et al.. “Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.” Practical radiation oncology (2020). PMID: 32222430 ↗

    L1GUIDELINECited in: Applicability and Caveats
  16. [16]

    Tjong MC, Louie AV, Singh AK et al.. “Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung - The Knockout Punch.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2022). PMID: 35221140 ↗

    L5RCTCited in: Applicability and Caveats
  17. [17]

    Bestvina CM, Pointer KB, Karrison T et al.. “A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2021). PMID: 34500113 ↗

    L1RCTCited in: Applicability and Caveats
  18. [18]

    Zelefsky MJ, Yamada Y, Greco C et al.. “Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.” International journal of radiation oncology, biology, physics (2021). PMID: 33422612 ↗

    L1RCTCited in: Applicability and Caveats
  19. [19]

    Kim KH, Yoon S, Ahn HK et al.. “A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).” Clinical lung cancer (2022). PMID: 36002368 ↗

    L5TRIAL_NONRANDOMCited in: Applicability and Caveats
  20. [20]

    Navarria P, Baldaccini D, Clerici E et al.. “Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.” International journal of radiation oncology, biology, physics (2022). PMID: 35987453 ↗

    L2TRIAL_NONRANDOMCited in: Applicability and Caveats
  21. [21]

    Tsai CJ, Yang JT, Shaverdian N et al.. “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.” Lancet (London, England) (2023). PMID: 38104577 ↗

    L1RCTCited in: On the Horizon
  22. [22]

    Peng P, Gong J, Zhang Y et al.. “EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2023). PMID: 37105304 ↗

    L1RCTCited in: On the Horizon
  23. [23]

    Bassetti MF, Morris BA, Sethakorn N et al.. “Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.” International journal of radiation oncology, biology, physics (2023). PMID: 38072321 ↗

    L2TRIAL_NONRANDOMCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…